Vericel (VCEL) said Wednesday it has received approval for the commercial manufacturing of autologous cultured chondrocytes on porcine collagen membrane, or MACI, as its Massachusetts facility from the US Food and Drug Administration.
The approval allows Vericel to start commercial production of the knee cartilage repair product at the facility in Burlington in Q2, allowing it to meet increasing demand, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.